WallStreetZenWallStreetZen

NASDAQ: RNA
Avidity Biosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for RNA

Based on 10 analysts offering 12 month price targets for Avidity Biosciences Inc

Min Forecast
$62.00-14.98%
Avg Forecast
$69.80-4.28%
Max Forecast
$74.00+1.48%

Should I buy or sell RNA stock?

Based on 10 analysts offering ratings for Avidity Biosciences Inc.

Hold
Strong Buy
1 analysts 10%
Buy
1 analysts 10%
Hold
8 analysts 80%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their RNA stock forecasts and price targets.

RNA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-11
lockedlocked$00.00+00.00%2025-10-29
lockedlocked$00.00+00.00%2025-10-28
lockedlocked$00.00+00.00%2025-10-27
lockedlocked$00.00+00.00%2025-10-27
Bernstein
Bottom 14%
14
HoldDowngrades$72.00-1.26%2025-10-27
Needham
Top 1%
100
HoldDowngrades$65.00-10.86%2025-10-27
HC Wainwright & Co.
Top 18%
83
HoldDowngrades$72.00-1.26%2025-10-27
Evercore ISI Group
Top 2%
99
BuyMaintains$65.00-10.86%2025-09-22
Roth Capital
Top 12%
89
Strong BuyInitiates Coverage On$62.00-14.98%2025-09-17

1 of 1

Forecast return on equity

Is RNA forecast to generate an efficient return?

Company
19.52%
Industry
310.8%
Market
238.59%
RNA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RNA forecast to generate an efficient return on assets?

Company
17.26%
Industry
115.15%
RNA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RNA earnings per share forecast

What is RNA's earnings per share in the next 3 years based on estimates from 16 analysts?

Avg 1 year Forecast
-$5.20
Avg 2 year Forecast
-$4.38
Avg 3 year Forecast
-$1.23

RNA revenue forecast

What is RNA's revenue in the next 3 years based on estimates from 15 analysts?

Avg 1 year Forecast
$24.2M+16.02%
Avg 2 year Forecast
$297.0M+1,323.42%
Avg 3 year Forecast
$888.8M+4,159.01%
RNA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

RNA revenue growth forecast

How is RNA forecast to perform vs Biotechnology companies and vs the US market?

Company
239.56%
Industry
118.19%
Market
23.42%
RNA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RNA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RNA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RNA$72.92$69.80-4.28%Hold
MDGL$481.00$666.82+38.63%Strong Buy
EXEL$42.94$44.18+2.89%Buy
SMMT$15.25$33.29+118.27%Buy
BMRN$60.31$83.46+38.38%Strong Buy
View Top Biotech Stocks

Avidity Biosciences Stock Forecast FAQ

Is Avidity Biosciences Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 10 Wall Street analysts covering (NASDAQ: RNA) stock is to Hold RNA stock.

Out of 10 analysts, 1 (10%) are recommending RNA as a Strong Buy, 1 (10%) are recommending RNA as a Buy, 8 (80%) are recommending RNA as a Hold, 0 (0%) are recommending RNA as a Sell, and 0 (0%) are recommending RNA as a Strong Sell.

If you're new to stock investing, here's how to buy Avidity Biosciences stock.

What is RNA's earnings growth forecast for 2026-2028?

(NASDAQ: RNA) Avidity Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 68.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.82%.

Avidity Biosciences's earnings in 2026 is -$549,787,000.On average, 16 Wall Street analysts forecast RNA's earnings for 2026 to be -$782,820,750, with the lowest RNA earnings forecast at -$964,234,343, and the highest RNA earnings forecast at -$620,181,354. On average, 11 Wall Street analysts forecast RNA's earnings for 2027 to be -$660,472,047, with the lowest RNA earnings forecast at -$742,741,003, and the highest RNA earnings forecast at -$468,300,206.

In 2028, RNA is forecast to generate -$185,165,419 in earnings, with the lowest earnings forecast at -$512,387,928 and the highest earnings forecast at $240,478,484.

What is RNA's revenue growth forecast for 2026-2028?

(NASDAQ: RNA) Avidity Biosciences's forecast annual revenue growth rate of 239.56% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 118.19%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.42%.

Avidity Biosciences's revenue in 2026 is $20,868,000.On average, 15 Wall Street analysts forecast RNA's revenue for 2026 to be $3,648,010,390, with the lowest RNA revenue forecast at $0, and the highest RNA revenue forecast at $10,346,903,203. On average, 11 Wall Street analysts forecast RNA's revenue for 2027 to be $44,756,722,404, with the lowest RNA revenue forecast at $11,483,148,974, and the highest RNA revenue forecast at $90,607,350,694.

In 2028, RNA is forecast to generate $133,916,079,217 in revenue, with the lowest revenue forecast at $69,800,537,482 and the highest revenue forecast at $227,520,370,420.

What is RNA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: RNA) forecast ROA is 17.26%, which is lower than the forecast US Biotechnology industry average of 115.15%.

What is RNA's Price Target?

According to 10 Wall Street analysts that have issued a 1 year RNA price target, the average RNA price target is $69.80, with the highest RNA stock price forecast at $74.00 and the lowest RNA stock price forecast at $62.00.

On average, Wall Street analysts predict that Avidity Biosciences's share price could fall to $69.80 by Nov 11, 2026. The average Avidity Biosciences stock price prediction forecasts a potential downside of 4.28% from the current RNA share price of $72.92.

What is RNA's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: RNA) Avidity Biosciences's current Earnings Per Share (EPS) is -$4.19. On average, analysts forecast that RNA's EPS will be -$5.20 for 2026, with the lowest EPS forecast at -$6.40, and the highest EPS forecast at -$4.12. On average, analysts forecast that RNA's EPS will be -$4.38 for 2027, with the lowest EPS forecast at -$4.93, and the highest EPS forecast at -$3.11. In 2028, RNA's EPS is forecast to hit -$1.23 (min: -$3.40, max: $1.60).

What is RNA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: RNA) forecast ROE is 19.52%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.